• Organizations: Sydnexis
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia
Pipeline

Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia

The STAR study met both primary and secondary endpoints for low-dose atropine formulation—just days after the FDA’s NDA rejection.
Viatris and Locus Biosciences to develop antibacterial therapies for ophthalmic infections
Research

Viatris and Locus Biosciences to develop antibacterial therapies for ophthalmic infections

Collaboration will utilize Locus’ advanced precision drug development platform to address increasing burden of antimicrobial resistance in eye infections.
FDA rejects Sydnexis’ NDA for low-dose atropine drop
Pipeline

FDA rejects Sydnexis’ NDA for low-dose atropine drop

SYD-101 still has the potential to become the first pharmaceutical option for progressive myopia for patients aged 3 to 14.
FDA accepts NDA for Sydnexis's low-dose atropine for pediatric myopia
Pipeline

FDA accepts NDA for Sydnexis's low-dose atropine for pediatric myopia

Once-daily drop features unique establishing excipient to avoid rapid atropine degradation; may become first eye drop with 3-year shelf-life.
Sydnexis names long-time industry executive as new leader
Business

Sydnexis names long-time industry executive as new leader

Effective Aug. 5, Perry J. Sternberg will take over as CEO of the pediatric myopia-focused pharmaceutical company.